ASCO GU 2024 Bladder Cancer - Results from #20

Viewing 21-40 of 53 articles

ASCO GU 2024: AMBASSADOR Alliance A031501: Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma Versus Observation (Late-Breaking Abstract)

ASCO GU 2024: Predicting Clinical Outcomes in the S1314-COXEN Trial Using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression

ASCO GU 2024: Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma (PemCab)

ASCO GU 2024: Avelumab First-Line Maintenance Therapy for Locally Advanced/metastatic Urothelial Carcinoma: Results from the Real-World US PATRIOT-II Study

ASCO GU 2024: GDFather-Neo - Neutralizing GDF-15 in MIBC: A Neoadjuvant Immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab

ASCO GU 2024: Enfortumab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma: Subgroup Analyses Results from EV-302, a Phase 3 Global Study

ASCO GU 2024: INVEST: A Phase Ib Window of Opportunity Study of Atezolizumab Administered Either Intravesically or Direct Tumor Injection in Patients with Bladder Cancer Prior to Radical Cystectomy

ASCO GU 2024: First Results of NURE-Combo: A Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Followed by Postsurgical Adjuvant Nivolumab in Patients with MIBC

ASCO GU 2024: Sequencing of Erdafitinib and Enfortumab Vedotin in Patients with FGFR2/3 Altered Advanced Urothelial Cancer: Analysis of UNITE Database

ASCO GU 2024: Interim Analysis of a Phase I/Ib Study of Enfortumab Vedotin plus Cabozantinib in Patients with Metastatic Urothelial Carcinoma

ASCO GU 2024: BladderGATE: Atezolizumab + intravesical BCG Upfront Combination in Patients with High-risk NMIBC—Phase I-II ONCOSUR Study

ASCO GU 2024: A Phase 1 Study of IO102-IO103 Vaccine Plus Pembrolizumab in Patients with BCG-intolerant or Unresponsive Non-Muscle Invasive Bladder Cancer

ASCO GU 2024: Pembrolizumab with Favezelimab or Vibostolimab for Patients with BCG–unresponsive High-risk Non–muscle-Invasive Bladder Cancer: Phase 2 KEYNOTE-057 Cohort C

ASCO GU 2024: PIVOT-006: A phase 3, Randomized Study of Cretostimogene Grenadenorepvec vs Observation for the Treatment of Intermediate Risk Non-muscle Invasive Bladder Cancer Following TURBT

ASCO GU 2024: Blue Light Cystoscopy Versus White Light Cystoscopy for the Detection of Bladder Cancer in China: An Analysis of Unpublished Clinical Trial and Real-World Data

ASCO GU 2024: BCG Shortage: What’s on the Horizon to Replace?

ASCO GU 2024: Punch: Preliminary Results from a Phase II Study of Intra‑arterial Chemotherapy Combined with Tislelizumab and BCG in High-Risk Non-Muscle-Invasive Bladder Cancer

ASCO GU 2024: SAKK 06/19 - Intravesical Recombinant BCG Followed by Perioperative Chemo-Immunotherapy for Patients with Muscle-Invasive Bladder Cancer: A Multicenter, Single Arm Phase 2 Trial

ASCO GU 2024: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer

ASCO GU 2024: Adverse Effects and Discontinuation of Pembrolizumab in BCG Refractory Non-Muscle Invasive Bladder Cancer

1
2
3